Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADLNASDAQ:CRVSNASDAQ:DSGNNASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$5.97+1.8%$5.14$3.79▼$14.60$298.86M-0.871.45 million shs138,368 shsCRVSCorvus Pharmaceuticals$4.12+2.1%$3.48$1.75▼$10.00$281.61M0.57746,418 shs167,974 shsDSGNDesign Therapeutics$4.09+4.5%$3.69$2.60▼$7.77$228.89M1.62183,846 shs10,507 shsRANIRani Therapeutics$0.59+2.4%$0.89$0.46▼$4.63$33.91M0.25807,661 shs121,006 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-2.98%+4.83%+22.08%-26.84%-18.04%CRVSCorvus Pharmaceuticals+3.32%+0.25%-8.80%-7.55%+99.01%DSGNDesign Therapeutics-2.49%-2.74%+12.03%-26.64%+1.56%RANIRani Therapeutics+2.52%+3.07%-21.36%-60.68%-86.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.2824 of 5 stars3.51.00.00.03.31.70.6CRVSCorvus Pharmaceuticals2.3155 of 5 stars3.51.00.00.02.62.50.6DSGNDesign Therapeutics0.5318 of 5 stars1.00.00.00.02.92.50.6RANIRani Therapeutics1.7194 of 5 stars3.61.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$21.00252.05% UpsideCRVSCorvus Pharmaceuticals 3.00Buy$15.00263.81% UpsideDSGNDesign Therapeutics 2.00Hold$4.00-2.08% DownsideRANIRani Therapeutics 3.20Buy$9.401,498.64% UpsideCurrent Analyst Ratings BreakdownLatest RANI, DSGN, CRVS, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/3/2025RANIRani TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.003/26/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/14/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,490.54N/AN/A$0.44 per share13.56CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.79 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/ARANIRani Therapeutics$1.20M28.17N/AN/A$0.51 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)CRVSCorvus Pharmaceuticals-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%8/5/2025 (Estimated)DSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)RANIRani Therapeutics-$33.97M-$0.99N/AN/AN/AN/A-219.64%-56.71%8/5/2025 (Estimated)Latest RANI, DSGN, CRVS, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 million5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A3/31/2025Q4 2024RANIRani Therapeutics-$0.24-$0.27-$0.03-$0.27N/A$1.03 million3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/A3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/A3/10/2025Q4 2024DSGNDesign Therapeutics-$0.28-$0.24+$0.04-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel TherapeuticsN/A1.181.18CRVSCorvus PharmaceuticalsN/A0.920.92DSGNDesign TherapeuticsN/A34.6134.61RANIRani Therapeutics2.341.601.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%CRVSCorvus Pharmaceuticals46.64%DSGNDesign Therapeutics56.64%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%CRVSCorvus Pharmaceuticals28.50%DSGNDesign Therapeutics31.20%RANIRani Therapeutics50.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableCRVSCorvus Pharmaceuticals3068.17 million44.15 millionOptionableDSGNDesign Therapeutics4056.77 million38.96 millionOptionableRANIRani Therapeutics11057.48 million26.75 millionOptionableRANI, DSGN, CRVS, and CADL HeadlinesRecent News About These CompaniesRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13, 2025 | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comStifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)April 23, 2025 | markets.businessinsider.comRani Therapeutics management to meet virtually with Lake StreetApril 17, 2025 | markets.businessinsider.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comRani Therapeutics reports Q4 EPS (27c), consensus (23c)April 1, 2025 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comRani Therapeutics Reports 2024 Financial Results and UpdatesMarch 31, 2025 | tipranks.comRani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comRani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate UpdateMarch 31, 2025 | globenewswire.comAn Overview of Rani Therapeutics Hldgs's EarningsMarch 28, 2025 | benzinga.comStifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)March 28, 2025 | markets.businessinsider.comRani announces pharmacokinetic, pharmacodynamic data from RT-114 trialMarch 27, 2025 | markets.businessinsider.comRani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102March 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeBy Nathan Reiff | June 9, 2025View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeRANI, DSGN, CRVS, and CADL Company DescriptionsCandel Therapeutics NASDAQ:CADL$5.96 +0.11 (+1.79%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Corvus Pharmaceuticals NASDAQ:CRVS$4.12 +0.08 (+2.05%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Design Therapeutics NASDAQ:DSGN$4.08 +0.18 (+4.48%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Rani Therapeutics NASDAQ:RANI$0.59 +0.01 (+2.42%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? As Gold Surges, Albemarle Stock May Be the Next to Pop Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
